Last reviewed · How we verify
MK-8237 12 DU
At a glance
| Generic name | MK-8237 12 DU |
|---|---|
| Also known as | SCH 900237 |
| Sponsor | ALK-Abelló A/S |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) (PHASE1)
- A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) (PHASE2)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-8237 12 DU CI brief — competitive landscape report
- MK-8237 12 DU updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI